Clinical trial NCT02647320: 12-Week Study of DS-8500a in Subjects With Type 2 Diabetes Mellitus on Metformin
Official title: A Randomized, Double-Blind, Placebo-Controlled With Active Comparator, 12-Week Study of DS-8500a in Subjects With Type 2 Diabetes Mellitus on Metformin
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Type 2 Diabetes Mellitus
Keywords: type 2 diabetes mellitus
interventional
double blind
phase 2
Lead sponsor: Daiichi Sankyo
Sponsor class: INDUSTRY
First posted: 2016-01-06
Enrollment: 298
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The hypothesis of this Phase 2, 12-week study, is that DS-8500a will improve glycemic control relative to placebo, based on changes in HbA1c, with acceptable safety and tolerability, in patients with Type 2 Diabetes Mellitus (T2DM) who are treated with metformin.


Eligibility criteria: Inclusion Criteria:

* Able to provide written informed consent and adhere to the study visit schedule and treatment
* Diagnosed with Type 2 diabetes mellitus as defined in the American Diabetes Association Standards of Medical Care in Diabetes 2015
* Male or female ≥ 18 and ≤ 70 years of age
* Screening fasting C-peptide \> 0.5 ng/mL
* Women of child bearing potential (WOCBP) must be willing to use double-barrier contraception for the entire study
* WOCBP must have a negative pregnancy test (human chorionic gonadotropin, beta subunit \[βhCG\]) before entering the Lead-in Period
* Body mass index ≥ 25 kg/m2 and ≤ 45 kg/m2 at the Screening Visit
* On stable (≥ 8 weeks) metformin monotherapy ≥ 1000 mg/day
* Screening HbA1c ≥ 7.0% and ≤ 10%
* Taking ≥ 80% and ≤ 120% of both dispensed DS-8500a placebo tablets and sitagliptin placebo capsules during the Lead-in Period

Exclusion Criteria:

* History of type 1 diabetes and/or history of ketoacidosis
* History of insulin use for \> 2 weeks within 2 months prior to the Screening Visit
* Two or more readings of fasting Self-monitoring of Blood Glucose (SMBG) \> 240 mg/dL or worsening symptoms of hyperglycemia with one SMBG level of \> 240 mg/dL during the second week of Lead-in Period, confirmed by laboratory measurement
* Screening hemoglobin \<12 g/dL for males and \<11 g/dL for females
* Blood donation within 2 months prior to the Screening Visit or plans to donate blood or blood products during the study
* Subjects after bariatric surgery or any gastric bypass
* Screening thyroid stimulating hormone (TSH) levels not within normal range (based on reference laboratory values )
* Screening Alanine Aminotransferase (ALT) or Aspartate Aminotransferase (AST) \> 2.0 x upper limit of normal (ULN), and/or total bilirubin \> 1.5 x ULN. If a subject has total bilirubin \> 1.5 ULN, unconjugated and conjugated bilirubin fractions should be analyzed and only subjects documented to have Gilbert's syndrome may be enrolled
* Screening Serum creatinine ≥ 1.5 mg/dL for males and ≥ 1.4 mg/dL for females, or creatinine clearance (CrCl) \< 50 mL/min for both males and females
* Screening Creatine kinase (CK) \> 3.0 × ULN
* History of unstable angina, myocardial infarction, cerebrovascular accident, transient ischemic attack, peripheral arterial event or any revascularization procedure during the 6 months prior to the Screening Visit or planned vascular procedures or surgery during study period
* History of congestive heart failure (CHF)
* Exclusionary concomitant medications:

  a. Eight weeks prior to screening and throughout the duration of the study:
* Any diabetes medication other than metformin; any prescription or over the counter medication for weight-loss.
* Systemic corticosteroids (including nasal and inhaled), with the exception of use of topical and ophthalmic corticosteroids.
* Rosuvastatin \> 20 mg daily. b. During treatment periods, additional medications will be prohibited based on potential drug-drug interaction (DDI) (see Section 5.6)
* Subjects with anticipated interruption in metformin or study drug use during the course of the clinical trial (e.g., due to an imaging procedure involving iodinated contrast media)
* Subjects in whom treatment with sitagliptin 100 mg is contraindicated ( e.g., known hypersensitivity or intolerance to sitagliptin) or may not be medically advisable (e.g., history of pancreatitis)
* Abuse of or dependence on prescription medications, illicit drugs, or alcohol within the last 1 year
* Any history of a malignancy other than basal cell carcinoma within the past 5 years
* Pregnancy or breast-feeding, or intent to become pregnant during the study period
* Known (or evidence of) infection with human immunodeficiency virus
* Any condition, laboratory abnormality, or concomitant therapy which, in the opinion of the Investigator, might pose a risk to the subject or make participation not in the subject's best interest
* Subject is currently enrolled in or has not yet completed at least 30 days since ending another investigational device or drug study or is receiving other investigational agents
* A direct or familial relationship with the Sponsor, Investigator, or site personnel affiliated with the study

Primary outcomes:
measure: Change From Baseline in Glycated Hemoglobin (HbA1c) at Week 12
timeFrame: Baseline, Week 12
Secondary outcomes:
measure: Change From Baseline in Total Cholesterol (TC) at Week 12
timeFrame: Baseline, Week 12
measure: Change From Baseline in LDL-C at Week 12
timeFrame: Baseline, Week 12
measure: Change From Baseline in HDL-C at Week 12
timeFrame: Baseline, Week 12
measure: Change From Baseline in Non-HDL-C at Week 12
timeFrame: Baseline, Week 12
measure: Change From Baseline in Triglycerides at Week 12
timeFrame: Baseline, Week 12
measure: Change From Baseline in Area-Under-the Curve 0-3 Hours (AUC0-3h) of Plasma Glucose (PG) in Response to the Mixed Meal Tolerance Test (MMTT) at Week 4
timeFrame: Baseline, Week 4
measure: Change From Baseline in AUC0-3h of PG in Response to the MMTT at Week 12
timeFrame: Baseline, Week 12
measure: Change From Baseline in Maximum Concentration (Cmax) of PG in Response to MMTT at Week 4
timeFrame: Baseline, Week 4
measure: Change From Baseline in Cmax of PG in Response to MMTT at Week 12
timeFrame: Baseline, Week 12
measure: Change From Baseline in Fasting Plasma Glucose (FPG) at Week 2
timeFrame: Baseline, Week 2
measure: Change From Baseline in Fasting Plasma Glucose (FPG) at Week 4
timeFrame: Baseline, Week 4
measure: Change From Baseline in Fasting Plasma Glucose (FPG) at Week 8
timeFrame: Baseline, Week 8
measure: Change From Baseline in Fasting Plasma Glucose (FPG) at Week 12
timeFrame: Baseline, Week 12
measure: Count of Participants With HbA1c Less Than 7.0% at Week 12
timeFrame: Week 12
Other outcomes:
Locations:
city: Birmingham
country: United States
state: Alabama
city: Litchfield Park
country: United States
state: Arizona
city: Tempe
country: United States
state: Arizona
city: Anaheim
country: United States
state: California
city: Chino
country: United States
state: California
city: Chula Vista
country: United States
state: California
city: Fresno
country: United States
state: California
city: Gold River
country: United States
state: California
city: Greenbrae
country: United States
state: California
city: San Diego
country: United States
state: California
city: Colorado Springs
country: United States
state: Colorado
city: Lakewood
country: United States
state: Colorado
city: Hallandale Beach
country: United States
state: Florida
city: Miami
country: United States
state: Florida
city: Miami
country: United States
state: Florida
city: Pembroke Pines
country: United States
state: Florida
city: West Palm Beach
country: United States
state: Florida
city: Atlanta
country: United States
state: Georgia
city: Boise
country: United States
state: Idaho
city: Avon
country: United States
state: Indiana
city: Evansville
country: United States
state: Indiana
city: Franklin
country: United States
state: Indiana
city: Greenfield
country: United States
state: Indiana
city: Council Bluffs
country: United States
state: Iowa
city: Troy
country: United States
state: Michigan
city: Edina
country: United States
state: Minnesota
city: Washington
country: United States
state: Missouri
city: Omaha
country: United States
state: Nebraska
city: Mooresville
country: United States
state: North Carolina
city: Morgantown
country: United States
state: North Carolina
city: Winston-Salem
country: United States
state: North Carolina
city: Columbus
country: United States
state: Ohio
city: Medford
country: United States
state: Oregon
city: Charleston
country: United States
state: South Carolina
city: Charleston
country: United States
state: South Carolina
city: Greer
country: United States
state: South Carolina
city: Mount Pleasant
country: United States
state: South Carolina
city: Spartanburg
country: United States
state: South Carolina
city: Austin
country: United States
state: Texas
city: Dallas
country: United States
state: Texas
city: Houston
country: United States
state: Texas
city: Plano
country: United States
state: Texas
city: San Antonio
country: United States
state: Texas
city: San Antonio
country: United States
state: Texas
city: Salt Lake City
country: United States
state: Utah
city: Salt Lake City
country: United States
state: Utah
city: South Jordan
country: United States
state: Utah
city: Burke
country: United States
state: Virginia
city: Victoria
country: Canada
state: British Columbia
city: Brampton
country: Canada
state: Ontario
city: London
country: Canada
state: Ontario
city: Newmarket
country: Canada
state: Ontario
city: Toronto
country: Canada
state: Ontario
city: Toronto
country: Canada
state: Ontario
city: Mirabel
country: Canada
state: Quebec
city: Montreal
country: Canada
state: Quebec
city: Sherbrooke
country: Canada
state: Quebec
city: Quebec
country: Canada
Study officials:
affiliation: Daiichi Sankyo
name: Clinical Study Leader
role: STUDY_DIRECTOR
References: